Institut fur Diabetes Karlsburg GmbH
14
0
0
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
System Accuracy and Performance Evaluation by the User of BGM LS-9
Role: lead
System Accuracy of 14 Blood Glucose Monitoring Systems
Role: lead
Performance Evaluation by the User of BGM Contour Care According to ISO 15197:2015
Role: lead
System Accuracy of the Blood Glucose Monitor for Personal Use Contour Care
Role: lead
System Accuracy of BGM GL22
Role: lead
User Evaluation of BGM JS200B
Role: lead
User Evaluation of BGM VGM77
Role: lead
System Accuracy of BGM GL60
Role: lead
System Accuracy of 12 Bloog Glucose Monitoring Systems
Role: lead
Hematocrit Effect on a Blood Glucose Monitor
Role: lead
System Accuracy of a Blood Glucose Monitoring System GlucoSpark/GlucoScore
Role: lead
System Accuracy of the Blood Glucose Monitor for Personal Use JT100
Role: lead
System Accuracy of the Blood Glucose Monitor for Personal Use BG-709b
Role: lead
Blood Glucose Monitoring Systems: Discounter Versus Brand
Role: lead
All 14 trials loaded